Concurrent exercise program changes PCSK9 in adults with overweight

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study will enroll 42 adults aged 18-40 with BMI 25.0–29.9 and randomly assign them to either a supervised concurrent exercise program three days per week for eight weeks or to continue usual activities. The program includes about 60 minutes per session of aerobic and resistance training with warm-up and cool-down. Researchers will measure serum PCSK9, lipid profiles, glucose, and body composition before and after the intervention to see how exercise affects cholesterol regulation. The study will also explore how PCSK9 relates to changes in body composition. The lead sponsor is Kastamonu University and the study will take place at Kastamonu University facilities in Turkey.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adults aged 18-40 years.
* Body mass index (BMI) between 25.0 and 29.9 kg/m².
* No participation in a regular exercise program during the previous two months (3-5 days per week, totaling 150 minutes per week).

Exclusion Criteria:

* Diagnosed coronary artery disease, heart failure, hypertension, diabetes mellitus, or other chronic cardiovascular or metabolic diseases.
* Acute or chronic inflammatory disease or active infection.
* History of malignancy or active cancer.
* Neurological, orthopedic, or musculoskeletal conditions that prevent participation in physical exercise.
* Current use of antihypertensive, lipid-lowering, antidiabetic, systemic glucocorticoid, or other medications that may affect PCSK9 levels.
* Current smoking or use of other tobacco products.
* Pregnancy or breastfeeding.
* Loss of 5% or more of body weight during the previous three months or participation in a weight-loss diet.
* Bariatric surgery or use of pharmacological weight-management treatment during the previous three months.

Where it's running

• Kastamonu University, Çatalzeytin Vocational School
  Çatalzeytin, Kastamonu, Turkey (Türkiye) Recruiting

Study contacts

• Study coordinator: Yasin Ak, PhD
• Email: fztyaso5@gmail.com
• Phone: +90 538 443 96 25

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

• Monthly dose of PF-08653944 vs placebo in Chinese adults who are overweight or obese

  This study tests whether berobenatide (PF-08653944) given once a month helps adults in China lose weight compared with a placebo.

  Recruiting Phase 3 Pfizer · Hefei, Anhui and 5 other locations · NCT07874633

• FutureShape Family: a family-based weight-management program with semaglutide for children and parents

  This trial tests whether a family-centered program that combines a prescription medication (semaglutide) with lifestyle support and app-based coaching can help adults with obesity and their children who are overweight/obese.

  Recruiting Phase 4 University of Copenhagen · Copenhagen · NCT07872904

• Home self-administration of a weight-management medicine with an autoinjector in adults who are overweight or obese

  This study tests whether adults who are overweight or have obesity can successfully self-administer maridebart cafraglutide at home using an autoinjector.

  Recruiting at 25 sites Phase 3 Amgen · San Diego, California and 24 other locations · NCT07871409

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.